Navigation Links
BioSpecifics Technologies Corp. To Present at Stifel Nicolaus Weisel Healthcare Conference 2012
Date:8/29/2012

LYNBROOK, N.Y., Aug. 29, 2012 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Europe and Eurasia, today announced that Thomas L. Wegman, President of BioSpecifics, will present at the Stifel Nicolaus Weisel Healthcare Conferences 2012 at 9:45 am EDT on Wednesday, September 5, 2012 in Boston, MA.

The live webcast of this presentation may be accessed under "Calendar of Events" in the Investor Relations section of BioSpecifics' website at www.biospecifics.com or at the link http://www.veracast.com/webcasts/stifel/healthcare2012/99104308.cfm. A replay of the webcast will also be available on the Company's website following the presentation.

About BioSpecifics Technologies Corp.
BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase (XIAFLEX®) for twelve clinical indications. Currently, XIAFLEX is marketed in the U.S. for the treatment of adult Dupuytren's contracture patients with a palpable cord by Auxilium Pharmaceuticals, Inc. (Auxilium) and is also in clinical development for the treatment of several additional promising indications. Auxilium has reported positive top-line results from two recently completed Phase III clinical trials for Peyronie's disease and is also testing XIAFLEX for frozen shoulder syndrome (adhesive capsulitis) and cellulite in Phase IIa and Phase Ib clinical trials, respectively. BioSpecifics is currently managing the clinical development of XIAFLEX for the treatment of human lipoma and canine lipoma, which are both in Phase II clinical trials.  Auxilium has entered into three strategic partnerships for development and commercialization outside the U.S. of injectable collagenase for Dupuytren's contracture and Peyronie's disease. Pfizer Inc. has rights in Europe and Eurasia and injectable collagenase is currently marketed as XIAPEX® for Dupuytren's contracture in select European countries. Asahi Kasei Pharma Corporation has rights in Japan and Actelion Pharmaceuticals Canada Inc. has rights in Canada, Australia, Brazil and Mexico. For more information, please visit www.biospecifics.com.

 


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2012 Financial Results on August 9, 2012
2. BioSpecifics Technologies Corp. Announces Rescheduled First Quarter 2012 Financial Results Conference Call to May 10, 2012
3. Antifungal Drugs: Technologies and Global Markets
4. Cleveland Clinics 2012 Medical Innovation Summit Highlights Orthopaedic Technologies
5. Breast Cancer Diagnostic and Drug Technologies: Global Markets
6. ARAMARK Healthcare Technologies Taps Robert Steele to Lead ReMedPar
7. Montmed to Participate in 2013 Advanced Technologies and Treatments for Diabetes Conference
8. U.S. Navy Awards Multi-Million Dollar Contract to Innovation for Pharmacy Automation Technologies
9. Technologies Impacting the Future of Healthcare
10. ECRI Institute Helps Hospitals Design Spaces for Current and Future Technologies
11. Patient Safety Technologies Reports Second Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec 8, 2016 Research and ... Market Analysis and Trends - Adhesion Type, Application, Usability - Forecast ... ... Global Cardiology Electrodes Market is poised to grow at a CAGR ... trends that the market is witnessing include advancements in extracellular microelectrode ...
(Date:12/8/2016)... 8, 2016   TriNetX , the health ... Hospital signed a membership agreement to join ... of new cures. The TriNetX network ... million patients globally, biopharmaceutical companies and contract research ... protocol design, site selection, patient recruitment, and collaborative ...
(Date:12/8/2016)... 2016  Pennsylvania Physician General Dr. Rachel ... Programs Gary Tennis released safe prescribing ... benzodiazepines, developed with the help of a task ... are frequently prescribed for anxiety or insomnia," said ... opioid pain medications, benzodiazepines pose a significant risk ...
Breaking Medicine Technology:
(Date:12/9/2016)... , ... December 09, 2016 , ... ... at The Pierre Hotel in New York, NY, on December 3rd, to benefit ... and physicians attended the annual event, which raised over $1 million - the ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Pennsylvania Athletic Trainers’ Society ... the summer of 2016. The program was made possible by a Pennsylvania Department ... of Health and Human Services Administration. The broadcast, Use Your Head: Properly ...
(Date:12/8/2016)... ... December 08, 2016 , ... After enjoying ... opened registration today for its 33rd Annual Issues & Research Conference, March ... The theme of the conference is “Persistent Challenges and New Opportunities: Using Research ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... a Property owned by an affiliate of Seavest, has won a prestigious national ... Southern Chester County ambulatory care center (ACC) was named “Best New Development, MOBs ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental ... Your Mouth?” (WIYM) campaign to inform dentists and patients about the safety issues related ... and prosthetic market in the U.S. is projected to reach $6.4 billion in 2018 ...
Breaking Medicine News(10 mins):